Two Sigma Advisers
SGMO

Two Sigma Advisers’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Two Sigma Advisers’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4,343,255
Closed -$1.82M – 1788
2025
Q4 		$1.82M Buy
4,343,255
+2,234,900
+106% +$1.18M ﹤0.01% 1226
2025
Q3 		$1.42M Buy
2,108,355
+901,621
+75% +$486K ﹤0.01% 1285
2025
Q2 		$653K Buy
1,206,734
+307,479
+34% +$183K ﹤0.01% 1629
2025
Q1 		$590K Buy
899,255
+191,700
+27% +$203K ﹤0.01% 1706
2024
Q4 		$722K Buy
+707,555
New +$1.29M ﹤0.01% 1620
2024
Q3 		– Sell
-820,355
Closed -$294K – 2498
2024
Q2 		$294K Sell
820,355
-607,900
-43% -$328K ﹤0.01% 2074
2024
Q1 		$957K Sell
1,428,255
-657,000
-32% -$477K ﹤0.01% 1600
2023
Q4 		$1.13M Buy
2,085,255
+1,242,300
+147% +$573K ﹤0.01% 1584
2023
Q3 		$506K Sell
842,955
-167,900
-17% -$180K ﹤0.01% 1789
2023
Q2 		$1.31M Sell
1,010,855
-62,800
-6% -$85.8K ﹤0.01% 1422
2023
Q1 		$1.89M Sell
1,073,655
-120,100
-10% -$343K ﹤0.01% 1301
2022
Q4 		$3.75M Buy
1,193,755
+109,100
+10% +$423K 0.01% 899
2022
Q3 		$5.32M Buy
1,084,655
+498,900
+85% +$2.56M 0.02% 707
2022
Q2 		$2.42M Buy
585,755
+18,900
+3% +$81.7K 0.01% 1112
2022
Q1 		$3.29M Sell
566,855
-208,800
-27% -$1.24M 0.01% 1001
2021
Q4 		$5.82M Sell
775,655
-186,400
-19% -$1.62M 0.01% 701
2021
Q3 		$8.67M Sell
962,055
-61,100
-6% -$604K 0.02% 567
2021
Q2 		$12.2M Sell
1,023,155
-382,200
-27% -$4.33M 0.03% 489
2021
Q1 		$17.6M Sell
1,405,355
-8,300
-0.6% -$112K 0.05% 390
2020
Q4 		$22.1M Buy
1,413,655
+49,800
+4% +$583K 0.06% 325
2020
Q3 		$12.9M Buy
1,363,855
+261,200
+24% +$2.83M 0.04% 453
2020
Q2 		$9.88M Buy
1,102,655
+802,000
+267% +$7.44M 0.03% 561
2020
Q1 		$1.92M Buy
300,655
+131,600
+78% +$976K 0.01% 1141
2019
Q4 		$1.42M Buy
+169,055
New +$1.55M ﹤0.01% 1399
2019
Q3 		– Sell
-197,300
Closed -$2.13M – 2375
2019
Q2 		$2.13M Sell
197,300
-26,600
-12% -$283K 0.01% 1184
2019
Q1 		$2.14M Buy
223,900
+20,600
+10% +$210K 0.01% 1192
2018
Q4 		$2.33M Buy
203,300
+100,300
+97% +$1.25M 0.01% 1107
2018
Q3 		$1.75M Sell
103,000
-34,100
-25% -$518K ﹤0.01% 1297
2018
Q2 		$1.95M Sell
137,100
-108,555
-44% -$1.8M 0.01% 1307
2018
Q1 		$4.67M Sell
245,655
-44,824
-15% -$958K 0.01% 875
2017
Q4 		$4.76M Buy
290,479
+261,679
+909% +$3.89M 0.01% 865
2017
Q3 		$432K Buy
+28,800
New +$318K ﹤0.01% 1802
2017
Q1 		– Sell
-11,800
Closed -$36K – 2455
2016
Q4 		$36K Buy
+11,800
New +$43K ﹤0.01% 2307
2016
Q3 		– Sell
-36,555
Closed -$212K – 2301
2016
Q2 		$212K Buy
36,555
+20,555
+128% +$131K ﹤0.01% 1840
2016
Q1 		$97K Buy
16,000
+5,845
+58% +$35.1K ﹤0.01% 1940
2015
Q4 		$93K Buy
+10,155
New +$78.3K ﹤0.01% 1776
2015
Q1 		– Sell
-16,355
Closed -$249K – 2325
2014
Q4 		$249K Buy
16,355
+300
+2% +$3.64K ﹤0.01% 2069
2014
Q3 		$173K Sell
16,055
-8,600
-35% -$112K ﹤0.01% 2159
2014
Q2 		$376K Buy
+24,655
New +$355K ﹤0.01% 1861

Other funds holding SGMO

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Two Sigma Advisers's SGMO Position: Q1 2026 in Review

Two Sigma Advisers sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q1 2026, closing a stake of 4,343,255 shares — an estimated $1.82M sold.

Two Sigma Advisers first reported a position in SGMO in Q2 2014 and held it in 39 quarters. The position peaked at $22.1M in Q4 2020. 112 funds tracked by Wall St. Rank hold SGMO as of Q1 2026.

  • Two Sigma Advisers reported no remaining SANGAMO THERAPEUTICS INC position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 4,343,255 SANGAMO THERAPEUTICS INC shares in Q1 2026, an estimated $1.82M.
  • Two Sigma Advisers first reported a position in SANGAMO THERAPEUTICS INC in Q2 2014 and held it in 39 quarters.
  • Two Sigma Advisers's SANGAMO THERAPEUTICS INC position peaked at $22.1M in Q4 2020.
  • 112 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.